TEVA PHARMACEUTICAL INDUSTRIES LIMITED Net Income (Loss) Available to Common Stockholders, Diluted
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$576.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-29
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$576.00M, a 304.26% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $369.00M, a 72.43% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $480.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $433.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for fiscal 2025 was $1.41B.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for fiscal 2024 was -$1.64B.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for fiscal 2023 was -$559.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED net income (loss) available to common stockholders, diluted for fiscal 2022 was -$2.45B, a 686.57% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$576.00M 10-Q · filed 2026-07-29 | -$207.00M 10-Q · filed 2026-07-29 | $273.00M derived: sum of 3 quarters · filed 2026-07-29 | $706.00M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $369.00M 10-Q · filed 2026-04-29 | $849.00M derived: sum of 2 quarters · filed 2026-04-29 | $1.28B derived: sum of 3 quarters · filed 2026-04-29 | $1.56B derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $480.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | $913.00M derived: sum of 2 quarters · filed 2026-02-03 | $1.20B derived: sum of 3 quarters · filed 2026-07-29 | $1.41B 10-K · filed 2026-02-03 | |
| 2025-09-30 | $433.00M 10-Q · filed 2025-11-05 | $715.00M derived: sum of 2 quarters · filed 2026-07-29 | $930.00M 10-Q · filed 2025-11-05 | $712.00M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $282.00M 10-Q · filed 2026-07-29 | $497.00M 10-Q · filed 2026-07-29 | $279.00M derived: sum of 3 quarters · filed 2026-07-29 | -$158.00M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $214.00M 10-Q · filed 2026-04-29 | -$3.00M derived: sum of 2 quarters · filed 2026-04-29 | -$440.00M derived: sum of 3 quarters · filed 2026-04-29 | ||
| 2024-12-31 | -$217.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-03 | -$654.00M derived: sum of 2 quarters · filed 2026-02-03 | -$1.64B 10-K · filed 2026-02-03 | ||
| 2024-09-30 | -$437.00M 10-Q · filed 2025-11-05 | -$1.42B 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | -$559.00M 10-K · filed 2026-02-03 | ||||
| 2022-12-31 | -$2.45B 10-K · filed 2025-02-05 | -$2.35B 10-K · filed 2023-02-10 | |||
| 2021-12-31 | $417.00M 10-K · filed 2024-02-12 | ||||
| 2020-12-31 | -$3.99B 10-K · filed 2023-02-10 | ||||
| 2019-12-31 | -$999.00M 10-K · filed 2022-02-09 | ||||
| 2018-12-31 | -$2.40B 10-K · filed 2021-02-10 | ||||
| 2017-12-31 | -$16.52B 10-K · filed 2020-02-21 | ||||
| 2016-12-31 | $68.00M 10-K · filed 2019-02-19 | ||||
| 2015-12-31 | $1.57B 10-K · filed 2018-02-12 | ||||
| 2014-12-31 | $3.06B 20-F · filed 2017-02-15 | ||||
| 2013-12-31 | $1.27B 20-F · filed 2016-02-11 | ||||
| 2012-12-31 | $1.96B 20-F · filed 2015-02-09 | ||||
| 2012-03-31 | $859.00M 6-K · filed 2012-05-09 | $1.36B derived: sum of 2 quarters · filed 2014-02-10 | $2.28B derived: sum of 3 quarters · filed 2014-02-10 | $2.86B derived: sum of 4 quarters · filed 2014-02-10 | |
| 2011-12-31 | $506.00M derived: 20-F 12 month − 6-K 9 month · filed 2014-02-10 | $1.42B derived: sum of 2 quarters · filed 2014-02-10 | $2.00B derived: sum of 3 quarters · filed 2014-02-10 | $2.76B 20-F · filed 2014-02-10 | |
| 2011-09-30 | $916.00M 6-K · filed 2011-11-02 | $1.49B derived: sum of 2 quarters · filed 2011-11-02 | $2.25B 6-K · filed 2011-11-02 | $3.04B derived: sum of 4 quarters · filed 2013-02-12 | |
| 2011-06-30 | $576.00M 6-K · filed 2011-07-28 | $1.34B 6-K · filed 2011-07-28 | $2.12B derived: sum of 3 quarters · filed 2013-02-12 | $3.18B derived: sum of 4 quarters · filed 2013-02-12 | |
| 2011-03-31 | $761.00M 6-K · filed 2012-05-09 | $1.54B derived: sum of 2 quarters · filed 2013-02-12 | $2.60B derived: sum of 3 quarters · filed 2013-02-12 | $3.41B derived: sum of 4 quarters · filed 2013-02-12 | |
| 2010-12-31 | $782.00M derived: 20-F 12 month − 6-K 9 month · filed 2013-02-12 | $1.84B derived: sum of 2 quarters · filed 2013-02-12 | $2.65B derived: sum of 3 quarters · filed 2013-02-12 | $3.38B 20-F · filed 2013-02-12 | |
| 2010-09-30 | $1.06B 6-K · filed 2011-11-02 | $1.87B derived: sum of 2 quarters · filed 2011-11-02 | $2.59B 6-K · filed 2011-11-02 | $2.97B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-06-30 | $808.00M 6-K · filed 2011-07-28 | $1.53B 6-K · filed 2011-07-28 | $1.91B derived: sum of 3 quarters · filed 2012-02-17 | $2.57B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2010-03-31 | $724.00M 6-K · filed 2011-05-11 | $1.10B derived: sum of 2 quarters · filed 2012-02-17 | $1.76B derived: sum of 3 quarters · filed 2012-02-17 | $2.28B derived: sum of 4 quarters · filed 2012-02-17 | |
| 2009-12-31 | $379.00M derived: 20-F 12 month − 6-K 9 month · filed 2012-02-17 | $1.04B derived: sum of 2 quarters · filed 2012-02-17 | $1.56B derived: sum of 3 quarters · filed 2012-02-17 | $2.00B 20-F · filed 2012-02-17 | |
| 2009-09-30 | $659.00M 6-K · filed 2010-11-02 | $1.18B derived: sum of 2 quarters · filed 2010-11-02 | $1.62B 6-K · filed 2010-11-02 | ||
| 2009-06-30 | $522.00M 6-K · filed 2010-07-27 | $974.00M 6-K · filed 2010-07-27 | |||
| 2008-12-31 | $614.00M 20-F · filed 2011-02-15 |